Ozmosi | AP-306 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

AP-306

Alternative Names: AP-306, AP 306, AP306
Clinical Status: Active
Latest Update: 2026-06-09
Latest Update Note: Clinical Trial Update

Product Description

Alebund Pharmaceuticals is developing AP-306, a blood phosphorus lowering drug with a novel mechanism. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05764590)

Mechanisms of Action: NPT-iib Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Alebund Pharmaceuticals
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AP-306

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Hyperphosphatemia|Kidney Diseases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06712654

 AP306-HP-202

P2

Recruiting

Hyperphosphatemia|Kidney Diseases

2027-02-28

77%

2026-06-10

Primary Endpoints|Start Date|Treatments|Trial Status

CTR20252154

 CTR20252154

P1

Completed

Hyperphosphatemia|Kidney Diseases

2025-08-13

2026-03-22

Primary Completion Date|Start Date

Recent News Events

Date

Type

Title

03/17/2026

News Article

 Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

03/17/2026

News Article

 R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

01/07/2025

News Article

 Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

12/13/2023

News Article

 Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions